SG10202007417SA - Combination of an antiallergic agent with muscarinic antagonist and/or dopaminergic agonist for use in preventing/stopping of axial myopia in human - Google Patents

Combination of an antiallergic agent with muscarinic antagonist and/or dopaminergic agonist for use in preventing/stopping of axial myopia in human

Info

Publication number
SG10202007417SA
SG10202007417SA SG10202007417SA SG10202007417SA SG10202007417SA SG 10202007417S A SG10202007417S A SG 10202007417SA SG 10202007417S A SG10202007417S A SG 10202007417SA SG 10202007417S A SG10202007417S A SG 10202007417SA SG 10202007417S A SG10202007417S A SG 10202007417SA
Authority
SG
Singapore
Prior art keywords
stopping
human
preventing
combination
muscarinic antagonist
Prior art date
Application number
SG10202007417SA
Other languages
English (en)
Inventor
Enzo Maria D'ambrosio
Original Assignee
Dambrosio Enzo Maria
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dambrosio Enzo Maria filed Critical Dambrosio Enzo Maria
Publication of SG10202007417SA publication Critical patent/SG10202007417SA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/468-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035Isoindoles, e.g. phthalimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/53Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/535Perilla (beefsteak plant)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/10Ophthalmic agents for accommodation disorders, e.g. myopia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
SG10202007417SA 2016-02-19 2017-02-17 Combination of an antiallergic agent with muscarinic antagonist and/or dopaminergic agonist for use in preventing/stopping of axial myopia in human SG10202007417SA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITUB2016A000876A ITUB20160876A1 (it) 2016-02-19 2016-02-19 Combinazione di un agente antiallergico con un antagonista muscarinico e/o un agonista dopaminergico per l'uso in prevenzione/ arresto di miopia assiale nell’uomo

Publications (1)

Publication Number Publication Date
SG10202007417SA true SG10202007417SA (en) 2020-09-29

Family

ID=55948995

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201806599SA SG11201806599SA (en) 2016-02-19 2017-02-17 Combination of an antiallergic agent with muscarinic antagonist and/or dopaminergic agonist for use in preventing/stopping of axial myopia in human
SG10202007417SA SG10202007417SA (en) 2016-02-19 2017-02-17 Combination of an antiallergic agent with muscarinic antagonist and/or dopaminergic agonist for use in preventing/stopping of axial myopia in human

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201806599SA SG11201806599SA (en) 2016-02-19 2017-02-17 Combination of an antiallergic agent with muscarinic antagonist and/or dopaminergic agonist for use in preventing/stopping of axial myopia in human

Country Status (13)

Country Link
US (2) US20200253951A1 (es)
EP (1) EP3416617A1 (es)
JP (1) JP2019505542A (es)
KR (1) KR20180117642A (es)
CN (1) CN108883060A (es)
AU (1) AU2017220640B2 (es)
BR (1) BR112018016845A2 (es)
CA (1) CA3013846A1 (es)
CL (1) CL2018002196A1 (es)
IL (1) IL260893B2 (es)
IT (1) ITUB20160876A1 (es)
SG (2) SG11201806599SA (es)
WO (1) WO2017140846A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201800005599A1 (it) * 2018-05-22 2019-11-22 Lente a contatto morbida
CN109044965A (zh) * 2018-10-17 2018-12-21 广州大光制药有限公司 格隆溴铵的眼用药物组合物及医药用途
CA3181292A1 (en) * 2020-06-02 2021-12-09 Andrei V. Tkatchenko Methods and compositions for preventing and treating myopia with levocabastine, a selective histamine h1-receptor antagonist, and derivatives thereof
CN114558069A (zh) * 2022-04-06 2022-05-31 杭州美依生物科技有限公司 一种眼部舒缓涂抹液及其制备方法
CN115137314B (zh) * 2022-09-02 2022-11-15 首都医科大学附属北京同仁医院 近视风险评估方法、装置及穿戴设备

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69029734T2 (de) 1989-06-21 1997-05-28 Univ Pennsylvania Verwendung von Pirenzepine, Telenzepine oder O-Methoxy -sila-hexocyclium zur Herstellung eines Medikaments zur BEHANDLUNG UND REGULIERUNG DER AUGENENTWICKLUNG
CA2567981C (en) 2004-05-28 2010-08-31 Schering Corporation Constrained himbacine analogs as thrombin receptor antagonists
EP1853592B1 (en) 2005-01-14 2011-03-02 Schering Corporation Synthesis of himbacine analogs
US20080050335A1 (en) * 2006-07-25 2008-02-28 Osmotica Corp. Ophthalmic Solutions
SG151148A1 (en) * 2007-10-05 2009-04-30 Singapore Health Services Pte Method and/or kit for determining response to muscarinic receptor antagonist treatment
ITMO20100369A1 (it) * 2010-12-30 2012-07-01 Enable Innovations Srl Gamma di prodotti per uso oftalmico.

Also Published As

Publication number Publication date
CL2018002196A1 (es) 2019-01-25
IL260893A (es) 2018-09-20
IL260893B1 (en) 2023-04-01
BR112018016845A2 (pt) 2018-12-26
US20230172904A1 (en) 2023-06-08
KR20180117642A (ko) 2018-10-29
AU2017220640B2 (en) 2022-08-25
SG11201806599SA (en) 2018-09-27
JP2019505542A (ja) 2019-02-28
CN108883060A (zh) 2018-11-23
WO2017140846A1 (en) 2017-08-24
EP3416617A1 (en) 2018-12-26
RU2018133026A (ru) 2020-03-19
AU2017220640A1 (en) 2018-10-04
US20200253951A1 (en) 2020-08-13
IL260893B2 (en) 2023-08-01
ITUB20160876A1 (it) 2017-08-19
RU2018133026A3 (es) 2020-04-24
CA3013846A1 (en) 2017-08-24

Similar Documents

Publication Publication Date Title
SG10202007417SA (en) Combination of an antiallergic agent with muscarinic antagonist and/or dopaminergic agonist for use in preventing/stopping of axial myopia in human
ZA201808186B (en) Agonist agents of cd47 inducing programmed cell death and their use in the treatments of diseases associated with defects in programmed cell death
PT3545948T (pt) Utilização de aglomerado de ouro ou substância que contém aglomerado de ouro na preparação de droga para prevenção e/ou tratamento de glaucoma
IL273031A (en) Combined treatment of lasmiditan and a CGRP antagonist for use in the treatment of migraine
EP3189834A4 (en) Use of gabaa receptor reinforcing agent in preparation of sedative and anesthetic medicament
IL280827A (en) Alpha 4 integrin antagonists and preparations containing them for use in the treatment of ocular disorders
PT3615035T (pt) Utilização de 20-hidroxiecdisona e os seus derivados no tratamento de miopatias
SG11201704756YA (en) Dislodgement and release of hsc using alpha 9 integrin antagonist and cxcr4 antagonist
GB201604213D0 (en) Drug combination and its use in therapy
ZA201902873B (en) Nutritional composition for use in therapy of patients with sarcopenia and/or frailty or pre-sarcopenic and/or pre-frail patients
ZA201900861B (en) Aza¿indazole compounds for use in tendon and/or ligament injuries
EP3509612A4 (en) CXCR4 ANTAGONISTS AND METHOD OF USE
EP3099304C0 (en) CHROMANE DERIVATIVES AND THEIR USE IN THE TREATMENT OF GLAUCOMA
EP3541378A4 (en) ALLOSTERIC ANTAGONISTS OF GPRC6A AND THEIR USE IN THE RELIEF OF PROTEINOPATHIA
EP3375781A4 (en) BENZORING DERIVATIVE WITH B2 RECEPTOR AGONIST AND M3 RECEPTOR ANTAGONIST ACTIVITIES AND USE THEREOF IN MEDICINE
HK1243327A1 (zh) 包含螺旋藻和棕櫚酰基乙醇酰胺和/或其鹽或藥用上可接受衍生物的組合及其製劑,用於預防和/或治療過度活化的組織病症
ZA201901740B (en) Pharmaceutical composition comprising mineralocorticoid receptor antagonist and use thereof
MX2016016667A (es) Métodos para tratar el cáncer y prevenir la resistencia a fármacos contra el cáncer.
IL274868A (en) History of imidazopyridine and their use as medicine
IL262546B (en) Use of an acetylcholinesterase inhibitor and idalopyridine to reduce falls in Parkinson's patients
EP3558378A4 (en) LOW DOSE COMBINATION OF MEDICINAL PRODUCTS FOR THE PREVENTION AND TREATMENT OF NEURAL DAMAGE
IL261182B (en) Leptin antagonist for use in the treatment of ischemia and reperfusion injury
ZA201804198B (en) Composition of olivetol and method of use reduce or inhibit the effects of tetrahydrocannabinol in the human body
ZA201808361B (en) Benzoxazine or quinazoline derivatives for use in the treatment of alzheimer¿s disease